Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ETCompany ParticipantsZack Armen - Head of Investor RelationsGaro Armen ...

A WARRINGTON cancer specialist is one of three researchers at the centre of a new fundraising appeal. The Christie Charity, ...

neoadjuvant therapy in breast cancer, total neoadjuvant therapy in rectal cancer, and the use of biomarkers to inform ...

Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

People with the dMMR gene mutation, which most often presents in colorectal cancer, are the best candidates for this novel ...

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...

Prof. Louise Emmett: "This collaborative Frontiers grant gives us the tools to deeply evaluate optimal combinations with targeted alpha therapy in prostate cancer – aiming for longer better ...

Investigators assessed whether a reported survival disadvantage in men with secondary rectal cancer following prostate cancer radiation therapy vs primary rectal cancer is due to patient ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...